Fulltext

The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer

Weiss, GJ ; Rosell, R. ; Fossella, F. ; Perry, M. ; Stahel, R. ; Barata, F. ; Nguyen, B. ; Paul, S. ; McAndrews, P. ; Hanna, N. ; Kelly, K. ; Bunn, PA

In: Annals of Oncology, 2007, vol. 18, no. 3, p. 453-460

Ajouter à la liste personnelle
    Titre
    • The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer
    Auteur
    • Weiss, GJ. Division of Medical Oncology, University of Colorado Health Sciences Center, Aurora, CO, USA
    • Rosell, R.. Catalan Institute of Oncology, Barcelona, Spain
    • Fossella, F.. MD Anderson Cancer Center, Houston, TX
    • Perry, M.. University of Missouri, Ellis Fischel Cancer Center, Columbia, MO, USA
    • Stahel, R.. University Hospital Division of Medical Oncology, Zurich, Switzerland
    • Barata, F.. Centro Hospitalar de Coimbra, Coimbra, Portugal
    • Nguyen, B.. Eli Lilly and Company, Indianapolis, IN
    • Paul, S.. Eli Lilly and Company, Indianapolis, IN
    • McAndrews, P.. Eli Lilly and Company, Indianapolis, IN
    • Hanna, N.. Indiana University Medical Center, Indianapolis, IN, USA
    • Kelly, K.. Division of Medical Oncology, University of Colorado Health Sciences Center, Aurora, CO, USA
    • Bunn, PA. Division of Medical Oncology, University of Colorado Health Sciences Center, Aurora, CO, USA
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Annals of Oncology, 2007, vol. 18, no. 3, p. 453-460. Oxford University Press
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:304054
    Summary
    Background: Using data from a large phase III study of previously treated advanced non-small-cell lung cancer (NSCLC) that showed similar efficacy for pemetrexed and docetaxel, this retrospective analysis evaluates the impact of first-line chemotherapy on the outcome of second-line chemotherapy. Patients and methods: In all, 571 patients with advanced NSCLC were randomly assigned to receive pemetrexed 500 mg/m2 or docetaxel 75 mg/m2 on day 1 of a 21-day cycle. Comparisons were made based on type of first-line therapy [gemcitabine + platinum (GP), taxane + platinum (TP), or other therapies (OT)], response to initial therapy, time since initial therapy, and clinical characteristics. The two second-line treatment groups were pooled for this analysis due to similar efficacy and were assumed to have no interaction with the first-line therapies. Results: Baseline characteristics were generally balanced. By multivariate analysis, gender, stage at diagnosis, performance status (PS), and best response to first-line therapy significantly influenced overall survival (OS). Additional factors by univariate analysis, histology, and time elapsed from first- to second-line therapy significantly influenced OS. Conclusions: Future trials in the second-line setting should stratify patients by gender, stage at diagnosis, PS, and best response to first-line therapy